Perrigo Company plc (NYSE:PRGO – Get Free Report) declared a quarterly dividend on Friday, November 1st, RTT News reports. Shareholders of record on Friday, November 29th will be given a dividend of 0.276 per share on Tuesday, December 17th. This represents a $1.10 dividend on an annualized basis and a yield of 4.23%.
Perrigo has increased its dividend payment by an average of 6.7% per year over the last three years and has increased its dividend annually for the last 22 consecutive years. Perrigo has a payout ratio of 34.6% meaning its dividend is sufficiently covered by earnings. Equities analysts expect Perrigo to earn $3.12 per share next year, which means the company should continue to be able to cover its $1.10 annual dividend with an expected future payout ratio of 35.3%.
Perrigo Price Performance
PRGO stock opened at $26.09 on Friday. The stock has a 50-day moving average price of $26.42 and a two-hundred day moving average price of $27.63. The stock has a market cap of $3.56 billion, a PE ratio of -28.36 and a beta of 0.48. The company has a current ratio of 1.99, a quick ratio of 1.24 and a debt-to-equity ratio of 0.80. Perrigo has a 1 year low of $23.89 and a 1 year high of $34.60.
Insider Activity at Perrigo
In related news, EVP Svend Andersen sold 28,300 shares of the firm’s stock in a transaction dated Tuesday, August 20th. The shares were sold at an average price of $27.75, for a total value of $785,325.00. Following the completion of the sale, the executive vice president now directly owns 73,553 shares in the company, valued at approximately $2,041,095.75. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. In other Perrigo news, EVP Ronald Craig Janish sold 13,000 shares of the firm’s stock in a transaction that occurred on Monday, August 26th. The shares were sold at an average price of $29.40, for a total transaction of $382,200.00. Following the completion of the sale, the executive vice president now directly owns 20,553 shares in the company, valued at $604,258.20. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, EVP Svend Andersen sold 28,300 shares of the firm’s stock in a transaction that occurred on Tuesday, August 20th. The stock was sold at an average price of $27.75, for a total transaction of $785,325.00. Following the sale, the executive vice president now owns 73,553 shares of the company’s stock, valued at $2,041,095.75. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 50,254 shares of company stock worth $1,411,969. Insiders own 0.70% of the company’s stock.
Wall Street Analyst Weigh In
Several equities analysts have recently weighed in on PRGO shares. Piper Sandler decreased their price objective on Perrigo from $36.00 to $35.00 and set an “overweight” rating for the company in a report on Thursday, July 11th. Canaccord Genuity Group restated a “buy” rating and issued a $42.00 price objective on shares of Perrigo in a report on Monday, September 30th. StockNews.com cut Perrigo from a “buy” rating to a “hold” rating in a report on Friday, October 25th. Finally, Jefferies Financial Group restated a “hold” rating and issued a $30.00 price objective (down previously from $50.00) on shares of Perrigo in a report on Monday, September 23rd. Two investment analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. According to data from MarketBeat, Perrigo presently has a consensus rating of “Moderate Buy” and a consensus target price of $37.00.
View Our Latest Stock Analysis on Perrigo
Perrigo Company Profile
Perrigo Company plc provides over-the-counter health and wellness solutions to enhance individual well-being in the United States, Europe, and internationally. It operates through Consumer Self-Care Americas and Consumer Self-Care International segments. The company develops, manufactures, markets, and distributes self-care consumer products, such as upper respiratory products, including cough suppressants, expectorants, and sinus and allergy relief; nutrition products consisting of infant formulas and nutritional beverages; digestive health products, including antacids, anti-diarrheal, and anti-heartburn; pain and sleep-aids products comprising pain relievers and fever reducers; and oral care products, which include toothbrushes, toothbrush replacement heads, floss, flossers, whitening products, and toothbrush covers.
Featured Stories
- Five stocks we like better than Perrigo
- How to Use the MarketBeat Stock Screener
- Battle of the Retailers: Who Comes Out on Top?
- The Significance of Brokerage Rankings in Stock Selection
- HCA Healthcare: Temporary Setbacks, Long-Term Strength
- What Does a Stock Split Mean?
- MarketBeat Week in Review – 10/28 – 11/1
Receive News & Ratings for Perrigo Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Perrigo and related companies with MarketBeat.com's FREE daily email newsletter.